New York State Common Retirement Fund Has $174,000 Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

New York State Common Retirement Fund lowered its position in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 10.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,959 shares of the biopharmaceutical company’s stock after selling 2,115 shares during the quarter. New York State Common Retirement Fund’s holdings in Puma Biotechnology were worth $174,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Fred Alger Management LLC lifted its stake in Puma Biotechnology by 6.2% in the first quarter. Fred Alger Management LLC now owns 3,626,637 shares of the biopharmaceutical company’s stock valued at $35,251,000 after acquiring an additional 210,634 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Puma Biotechnology by 3.5% during the 1st quarter. BlackRock Inc. now owns 3,100,594 shares of the biopharmaceutical company’s stock worth $30,138,000 after buying an additional 104,579 shares during the last quarter. Palo Alto Investors LP lifted its stake in shares of Puma Biotechnology by 1.4% during the 1st quarter. Palo Alto Investors LP now owns 1,392,997 shares of the biopharmaceutical company’s stock worth $13,540,000 after buying an additional 19,100 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Puma Biotechnology by 8.2% during the 1st quarter. Acadian Asset Management LLC now owns 1,215,477 shares of the biopharmaceutical company’s stock worth $11,814,000 after buying an additional 91,945 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Puma Biotechnology by 18.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 825,462 shares of the biopharmaceutical company’s stock worth $8,024,000 after buying an additional 127,529 shares during the last quarter. Hedge funds and other institutional investors own 85.05% of the company’s stock.

Shares of Puma Biotechnology stock opened at $6.64 on Tuesday. Puma Biotechnology, Inc. has a twelve month low of $6.48 and a twelve month high of $14.14. The company has a quick ratio of 1.16, a current ratio of 1.22 and a debt-to-equity ratio of 2.33. The company has a 50-day simple moving average of $7.42 and a two-hundred day simple moving average of $9.14. The stock has a market capitalization of $270.77 million, a price-to-earnings ratio of -7.38 and a beta of 1.13.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, August 5th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.18. Puma Biotechnology had a negative net margin of 13.77% and a negative return on equity of 355.42%. The business had revenue of $53.40 million during the quarter, compared to analysts’ expectations of $51.01 million. On average, sell-side analysts anticipate that Puma Biotechnology, Inc. will post -0.08 earnings per share for the current fiscal year.

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 5,332 shares of the firm’s stock in a transaction dated Friday, July 2nd. The shares were sold at an average price of $8.84, for a total value of $47,134.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders sold 11,182 shares of company stock worth $93,217. Insiders own 19.50% of the company’s stock.

PBYI has been the subject of a number of research reports. The Goldman Sachs Group cut their target price on shares of Puma Biotechnology from $9.00 to $8.00 and set a “sell” rating for the company in a research note on Friday, August 6th. Royal Bank of Canada cut their target price on shares of Puma Biotechnology from $13.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, August 6th.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use.

See Also: Basic Economics creates winners and losers

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.